雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Anti-VEGF drug therapy for aflibercept-resistant age-related macular degeneration Fumitaka Takii 1 , Eri Kimura 1 , Ryo Baba 1 , Kosei Yanagida 1 , Rei Nemoto 1 , Shunichiro Ueda 1 , Hayate Nakagawa 1 , Masahiro Miura 1 1Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center pp.353-360
Published Date 2024/3/15
DOI https://doi.org/10.11477/mf.1410215124
  • Abstract
  • Look Inside
  • Reference

Abstract Purpose:We assessed the therapeutic effects of faricimab and brolucizumab in cases of aflibercept-resistant age-related macular degeneration.

Patients and Methods:We evaluated 15 eyes from 15 patients with age-related macular degeneration that showed no improvement despite receiving two consecutive intravitreal aflibercept injections. An intravitreal faricimab injection was administered 8 weeks following the intravitreal aflibercept injection. If a clear therapeutic effect was not observed 8 weeks after the intravitreal faricimab injection, an intravitreal brolucizumab injection was administered, and its effectiveness was assessed 8 weeks after the injection.

Results:Improvement in findings was observed in only one of the 15 eyes(7%)after the intravitreal faricimab injection. Upon switching to intravitreal brolucizumab injection, improvement was observed in 10 of 14 eyes(71%). There was no significant difference in mean central macular thickness before and after the intravitreal faricimab injection(p=0.71, 15 eyes). Conversely, the mean central macular thickness significantly decreased after intravitreal brolucizumab injection compared to that before the injection(p=0.003, 14 eyes).

Conclusion:Brolucizumab showed a greater effectiveness than that of faricimab in treating age-related macular degeneration resistant to aflibercept therapy.


Copyright © 2024, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院

関連文献

もっと見る

文献を共有